ArticleEndocrine connections2025
Thermal ablation for papillary thyroid microcarcinoma in the isthmus: a systematic review and meta-analysis.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment strategy for isthmic papillary thyroid microcarcinoma (PTMC) remains controversial. Although preliminary studies have confirmed the safety and efficacy of thermal ablation (TA), systematic reviews focusing on isthmic PTMC are lacking. This study is the first meta-analysis to comprehensively evaluate the clinical value of TA for isthmic PTMC. Methods: A comprehensive search was conducted across PubMed, EMBASE, Cochrane Library, and Web of Science databases from their establishment dates through February 21, 2025, aiming to locate relevant studies investigating TA-treated isthmic PTMC cases. Following PRISMA standards, two investigators independently carried out three essential procedures: screening eligible literature, collecting pertinent data, and assessing study quality through established evaluation criteria. Results: Five studies involving 364 patients were included. Primary outcomes showed that the volume reduction rate at 12 months post-TA was 98.27% (95% CI: 96.95-99.58), with 90.84% (95% CI: 70.08-100.00) achieving complete tumor disappearance. During follow-up, the local recurrence rate was 0.38% (3/364; 95% CI: 0.00-1.65), and the lymph node metastasis rate was 0.01% (1/364; 95% CI: 0.00-0.77). Regarding safety, the major complication rate was 0.06% (2/364; 95% CI: 0.00-0.09%), both transient voice hoarseness, with no severe complications or distant metastasis reported. Conclusion: TA demonstrates excellent tumor control and safety for isthmic PTMC. However, current evidence is limited by retrospective study designs (80%) and short follow-up periods (mean <5 years). Future large-scale, multicenter prospective studies with longer follow-up are needed. Registration information: Registration number: INPLASY202520104; date: February 23, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.